Biotechnology
Health
Therapy

Seres Therapeutics

$3.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-2.90%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MCRB and other stocks, options, ETFs, and crypto commission-free!

About MCRB

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. Read More It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Employees
145
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
127.39M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
456.88K
High Today
$3.12
Low Today
$2.93
Open Price
$3.09
Volume
432.59K
52 Week High
$9.26
52 Week Low
$2.02

Collections

Biotechnology
Health
Therapy
Technology
2015 IPO
US

MCRB Earnings

-$0.76
-$0.63
-$0.51
-$0.38
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.